Advertisement

OTC Nasacort Approved — Physician’s First Watch

Medical News |
October 15, 2013

OTC Nasacort Approved

By Kristin J. Kelley

The FDA has approved the first glucocorticoid — triamcinolone acetonide (Nasacort Allergy 24HR) — for over-the-counter treatment of nasal allergy symptoms. The once-daily spray is indicated for patients aged 2 years and older.

The dosing instructions differ among age groups, says the FDA. Additionally, the drug's label warns that growth in some children could be slowed. Pediatricians should be consulted if children are going to be treated for more than 2 months per year.

In August, an FDA advisory panel voted 10 to 6 to make Nasacort available without a prescription.

Reader Comments (2)

Bernice Washington Other Healthcare Professional, Pharmacology/Pharmacy, George Washington University Hospital

So glad Nasocort is approved for OTC. I've suffered with Rhinitis for more years than it has been a diagnosis (lol). Allergy meds, even then "non-drowsy" orals cause drowsiness, dizziness, euphoria or a wierd feeling. OTC Nasacort is good!

kathleen kai/RN Other Healthcare Professional, Other, tucson medical center/retired

i bought a bottle of nasacort in mexico.it works the best with
zyrtex. i can breathe easier.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement